Show simple item record

dc.contributor.authorAttia, Noha
dc.contributor.authorMashal, Mohamed
dc.contributor.authorPuras Ochoa, Gustavo
dc.contributor.authorPedraz Muñoz, José Luis ORCID
dc.date.accessioned2021-07-09T16:28:05Z
dc.date.available2021-07-09T16:28:05Z
dc.date.issued2021-06-07
dc.identifier.citationPharmaceutics 13(6) : (2021) // Article ID 843es_ES
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10810/52263
dc.description.abstractThe cell-based approach in gene therapy arises as a promising strategy to provide safe, targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism, mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses, optimization for clinical use is an ongoing challenge. On the way of improvement, genetically modified MSCs have been combined with various novel techniques and tools (e.g., exosomes, spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine.es_ES
dc.description.sponsorshipAuthors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and technical assistance. The Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16); the Spanish Ministry of Science and Innovation (GrantsPID2019-106199RB-C21).es_ES
dc.language.isospaes_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MCIU/PID2019-106199RB-C21es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectnon-viral gene deliveryes_ES
dc.subject3D-bioprintinges_ES
dc.subjecttransfectiones_ES
dc.subjectmesenchymal stem celles_ES
dc.subjectcell therapyes_ES
dc.subjectgene therapyes_ES
dc.subjectniosomees_ES
dc.subjectCOVID-19es_ES
dc.titleMesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospectses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-06-24T14:11:40Z
dc.rights.holder© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/6/843es_ES
dc.identifier.doi10.3390/pharmaceutics13060843
dc.departamentoesFarmacia y ciencias de los alimentos
dc.departamentoeuFarmazia eta elikagaien zientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).